Recurrent Vulvovaginal Candidiasis
Conditions
Keywords
Recurrent Vulvovaginal Candidiasis, Lactobacillus, reproductive tract flora
Brief summary
We are trying to determine if Clotrimazole vaginal tablets with oral Lactobacillus is better than Clotrimazole vaginal tablets in Preventing the Recurrence of vulvovaginalcandidiasis
Detailed description
vulvovaginal candidiasis is common disease in women. Its refractory and high recurrence rate has always been a clinical problem. Some cases even recur several times a year, and those who recur more than four times a year are diagnosed as recurrent vaginal candidal infection Candidiasis, RVVC）。 The common clinical regimen for VVC is to strengthen and consolidate clotrimazole vaginal tablets for up to 25 weeks. However, long-term antibiotic treatment will lead to the decrease of vaginal microflora and the disappearance of inflammation and pathogenic bacteria, which will greatly increase the probability of repeated infection and become a barrier to clinical treatment. If probiotics are added in the treatment, the abundance of lactobacillus can be ensured while antibiotic treatment is carried out, the homeostasis of reproductive tract flora can be reestablished, the defense mechanism can be improved fundamentally, and the re invasion of pathogenic bacteria can be reduced, which will become a new treatment idea and method for radical cure of refractory RVVC. We hypothesize that Clotrimazole vaginal tablets with oral Lactobacillus is better than Clotrimazole vaginal tablets in Preventing the Recurrence of vulvovaginalcandidiasis.
Interventions
DRUGclotrimazole vaginal tablets
Intensive treatment: clotrimazole vaginal tablets 500mg, every 72 hours, three consecutive times Consolidation treatment: clotrimazole vaginal tablets 500mg, once a week, 6 months
DRUGClotrimazole vaginal tablets+ Lactobacillus
Intensive treatment: clotrimazole vaginal tablets 500mg, every 72 hours, three consecutive times Consolidation treatment: clotrimazole vaginal tablets 500mg, once a week, 6 months Human Reproductive Tract Active Lactobacillus,4g,qd ,3months
Sponsors
Peking University Shenzhen Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 52 Years
Healthy volunteers
No
Inclusion criteria
* Women be at least 18 years of age * Have symptoms of vulva irritation and or abnormal discharge * Meet the clinical criteria for RVVC * Willing to participate in research
Exclusion criteria
1. Taking / injecting antibiotics in the past two weeks; 2. A woman who intends to be pregnant, pregnant or lactating; 3. Long term use of contraceptives and immunosuppressants; 4. Postmenopausal; 5. There was no same fixed sexual partner (RSP) before and after treatment 6. Patients with severe gastrointestinal diseases, including colorectal cancer, IBS, IBD, chronic or acute diarrhea, long-term constipation, etc., or receiving gastrointestinal surgery and abdominal surgery within one year, such as cholecystectomy; 7. Patients with severe heart, liver and kidney dysfunction, mental diseases, infectious diseases, tumors, severe anemia, and severe autoimmune diseases (such as rheumatoid arthritis, lupus erythematosus, etc.)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The cure rate of RVVC, | 6 months | The cure rate of RVVC, |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Recurrence of RVVC | 6 months | Recurrence of RVVC |
Countries
China
Outcome results
None listed